Treats elevated intraocular pressure (IOP). Sold as Azopt. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Brinzolamide (sold as Azopt), first approved Apr 1, 1998, with 1 new use approved and 0 published complete response letters.
| Brinzolamide | Part D | $37.0M | -2% | 49,720 |
| Azopt | Part D | $9.1M | -37% | 4,850 |
| Retinal Ganglion Cell Neuroprotection Under Prostaglandin AnaloguesGlaucoma · Association for Innovation and Biomedical Research on Light and Image | — | Not yet recruiting | Jul 20, 2025 |
| Efficacy of Simbrinza and Rocklatan vs Cosopt and LatanoprostOpen Angle Glaucoma · Prairie Eye Center | Phase 4 | Recruiting | Mar 19, 2025 |
| Apr 1, 1998 | AzoptNDA 20816 · New molecular entity | Sandoz | 11 | Marketed |
| Nov 27, 2020 | BrinzolamideANDA 209406 | Watson Labs Inc | 2 | Marketed |
| Aug 18, 2021 | BrinzolamideANDA 204884 | Bausch And Lomb | 1 | Marketed |
| Jul 28, 2023 | BrinzolamideANDA 211914 | Padagis US | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sandoz